NASDAQ:TRVI Trevi Therapeutics (TRVI) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free TRVI Stock Alerts $2.85 -0.09 (-3.06%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$2.82▼$3.1550-Day Range$2.12▼$3.7052-Week Range$0.97▼$4.00Volume172,685 shsAverage Volume278,875 shsMarket Capitalization$196.54 millionP/E RatioN/ADividend YieldN/APrice Target$8.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Trevi Therapeutics alerts: Email Address Trevi Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside198.2% Upside$8.50 Price TargetShort InterestHealthy1.51% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.39) to ($0.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.44 out of 5 starsMedical Sector468th out of 909 stocksPharmaceutical Preparations Industry209th out of 425 stocks 3.5 Analyst's Opinion Consensus RatingTrevi Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTrevi Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.51% of the outstanding shares of Trevi Therapeutics have been sold short.Short Interest Ratio / Days to CoverTrevi Therapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Trevi Therapeutics has recently decreased by 2.80%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldTrevi Therapeutics does not currently pay a dividend.Dividend GrowthTrevi Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TRVI. Previous Next 1.3 News and Social Media Coverage News SentimentTrevi Therapeutics has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Trevi Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for TRVI on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Trevi Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Trevi Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders27.46% of the stock of Trevi Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.76% of the stock of Trevi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Trevi Therapeutics are expected to decrease in the coming year, from ($0.39) to ($0.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Trevi Therapeutics is -9.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Trevi Therapeutics is -9.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTrevi Therapeutics has a P/B Ratio of 2.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Trevi Therapeutics Stock (NASDAQ:TRVI)Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.Read More TRVI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TRVI Stock News HeadlinesApril 20, 2024 | americanbankingnews.comCritical Analysis: Pliant Therapeutics (NASDAQ:PLRX) vs. Trevi Therapeutics (NASDAQ:TRVI)April 9, 2024 | finance.yahoo.comTrevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International ConferenceApril 24, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 9, 2024 | prnewswire.comTrevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International ConferenceApril 4, 2024 | uk.investing.comTrevi Therapeutics appoints new VP for clinical developmentApril 4, 2024 | prnewswire.comTrevi Therapeutics to Participate in Upcoming April EventsApril 2, 2024 | finance.yahoo.comTrevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership TeamMarch 29, 2024 | msn.comTourists throw over €1 million into Italy’s Trevi Fountain each year. Here’s what happens to itApril 24, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…March 28, 2024 | msn.comTrevi Italian Restaurant at Forum Shops unexpectedly closesMarch 27, 2024 | msn.comProminent Trevi Italian Restaurant Abruptly Closes at the Forum ShopsMarch 21, 2024 | insidermonkey.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | finanznachrichten.deTrevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business UpdatesMarch 20, 2024 | benzinga.comTrevi Therapeutics: Q4 Earnings InsightsMarch 20, 2024 | msn.comTRVI Stock Earnings: Trevi Therapeutics Beats EPS for Q4 2023March 20, 2024 | finance.yahoo.comTrevi Therapeutics Inc (TRVI) Announces Year-End Financials and Progress in Clinical TrialsMarch 17, 2024 | msn.comGloria Trevi Lights Up New York, Debuts ‘Zorra' Remix With NebulossaMarch 16, 2024 | msn.comGloria Trevi Lights Up New York, Debuts ‘Zorra’ Remix With NebulossaMarch 13, 2024 | finance.yahoo.comTrevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024March 7, 2024 | msn.comOne million Euro gets thrown into Rome’s Trevi Fountain each year. What happens next?February 29, 2024 | finance.yahoo.comprivate equity firms who own 35% along with institutions invested in Trevi Therapeutics, Inc. (NASDAQ:TRVI) saw increase in their holdings value last weekFebruary 28, 2024 | finance.yahoo.comTrevi Therapeutics to Participate in Upcoming March EventsFebruary 28, 2024 | prnewswire.comTrevi Therapeutics to Participate in Upcoming March EventsFebruary 24, 2024 | thestreet.comTrevi Therapeutics Inc.February 22, 2024 | finance.yahoo.comTRVI Mar 2024 2.000 callFebruary 18, 2024 | finance.yahoo.comTRVI Mar 2024 3.000 callFebruary 6, 2024 | finance.yahoo.comTrevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceSee More Headlines Receive TRVI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/20/2024Today4/23/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TRVI CUSIPN/A CIK1563880 Webwww.trevitherapeutics.com Phone(203) 304-2499FaxN/AEmployees25Year FoundedN/APrice Target and Rating Average Stock Price Target$8.50 High Stock Price Target$9.00 Low Stock Price Target$8.00 Potential Upside/Downside+198.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,070,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-31.51% Return on Assets-28.89% Debt Debt-to-Equity RatioN/A Current Ratio15.03 Quick Ratio15.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.29 per share Price / Book2.21Miscellaneous Outstanding Shares68,960,000Free Float50,024,000Market Cap$196.54 million OptionableOptionable Beta0.86 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMs. Jennifer L. Good (Age 59)Co-Founder, CEO, President & Director Comp: $781.85kDr. Thomas R. Sciascia M.D. (Age 71)Co-Founder & Chief Science Officer Comp: $530.48kDr. David J. Clark A.F.P.M. (Age 59)M.D., M.R.C.P., Chief Medical Officer Comp: $325.39kMs. Lisa Delfini (Age 54)Chief Financial Officer Mr. Christopher Galletta (Age 46)Controller & Chief Accounting Officer Katie McManusCommunications ManagerMr. Farrell Simon Pharm.D.Chief Commercial OfficerMs. Danine Summers (Age 66)Vice President of Medical Affairs More ExecutivesKey CompetitorsLifecore BiomedicalNASDAQ:LFCRZevra TherapeuticsNASDAQ:ZVRARigel PharmaceuticalsNASDAQ:RIGLOrganigramNASDAQ:OGIAlimera SciencesNASDAQ:ALIMView All CompetitorsInsiders & InstitutionsFrazier Life Sciences Management L.P.Bought 500,000 shares on 2/15/2024Ownership: 11.559%Opaleye Management Inc.Bought 829,100 shares on 2/15/2024Ownership: 3.970%WealthTrust Axiom LLCSold 30,000 shares on 2/5/2024Ownership: 0.099%Lisa DelfiniSold 785 sharesTotal: $1,585.70 ($2.02/share)Lisa DelfiniSold 711 sharesTotal: $1,564.20 ($2.20/share)View All Insider TransactionsView All Institutional Transactions TRVI Stock Analysis - Frequently Asked Questions Should I buy or sell Trevi Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trevi Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TRVI shares. View TRVI analyst ratings or view top-rated stocks. What is Trevi Therapeutics' stock price target for 2024? 2 Wall Street research analysts have issued 1-year price objectives for Trevi Therapeutics' shares. Their TRVI share price targets range from $8.00 to $9.00. On average, they anticipate the company's stock price to reach $8.50 in the next year. This suggests a possible upside of 198.2% from the stock's current price. View analysts price targets for TRVI or view top-rated stocks among Wall Street analysts. How have TRVI shares performed in 2024? Trevi Therapeutics' stock was trading at $1.34 on January 1st, 2024. Since then, TRVI shares have increased by 112.7% and is now trading at $2.85. View the best growth stocks for 2024 here. When is Trevi Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our TRVI earnings forecast. How were Trevi Therapeutics' earnings last quarter? Trevi Therapeutics, Inc. (NASDAQ:TRVI) issued its quarterly earnings data on Wednesday, March, 20th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.02. What ETF holds Trevi Therapeutics' stock? Simplify Propel Opportunities ETF holds 200,000 shares of TRVI stock, representing 0.58% of its portfolio. What other stocks do shareholders of Trevi Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Trevi Therapeutics investors own include Trevena (TRVN), Diffusion Pharmaceuticals (DFFN), Fulcrum Therapeutics (FULC), Genocea Biosciences (GNCA), Marker Therapeutics (MRKR), VYNE Therapeutics (VYNE), Akero Therapeutics (AKRO), Aldeyra Therapeutics (ALDX), AzurRx BioPharma (AZRX) and Chimerix (CMRX). When did Trevi Therapeutics IPO? Trevi Therapeutics (TRVI) raised $70 million in an initial public offering on Tuesday, May 7th 2019. The company issued 4,700,000 shares at $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets acted as the underwriters for the IPO and Needham & Company was co-manager. How do I buy shares of Trevi Therapeutics? Shares of TRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TRVI) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHow to camouflage a factory of 53,000 workersStansberry ResearchDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
